Secondary Immunity to Legionella Pneumophila and Th1 Activity Are Suppressed by Delta-9-tetrahydrocannabinol Injection
Overview
Authors
Affiliations
Resistance to infection with Legionella pneumophila is primarily dependent upon cell-mediated immunity rather than humoral immunity. Recent evidence suggests that activation of cell-mediated immunity depends on Th1 cells and activation of humoral immunity depends on Th2 cells. In this report, delta 9-tetrahydrocannabinol (THC), the major psychoactive cannabinoid of marijuana and an immunomodulator, suppressed development of secondary immunity to L. pneumophila, which correlated with a reduction in Th1 activity. BALB/c mice, infected with a primary sublethal dose of L. pneumophila, developed resistance to a larger challenge infection 3 to 4 weeks later. However, intravenous injection of THC (4 mg/kg of body weight) 1 day prior to primary infection resulted in increased mortality after the challenge infection. The level of anti-L. pneumophila antibodies in serum increased in both THC-treated and control mice; however, in the THC group IgG1 antibodies which are stimulated by Th2 cells were elevated while Th1-regulated, IgG2a antibodies were depressed. Furthermore, cultured splenocytes from THC-treated mice had less L. pneumophila-specific lymphoproliferation, indicating a deficiency in cell-mediated immunity. Normal mouse splenocytes treated in vitro with THC and pokeweed mitogen showed suppressed production of gamma interferon, a cytokine associated with Th1 cells, but increased production of interleukin 4, a cytokine produced by Th2 cells. Splenocytes from THC-treated mice, stimulated in vitro with either pokeweed mitogen or anti-CD3 antibodies, also produced less gamma interferon, indicating less Th1 activity in these mice. These results suggest that THC decreases the development of anti-L. pneumophila immunity by causing a change in the balance of Th1 and Th2 activities.
Cannabis use, oral dysbiosis, and neurological disorders.
Hazzard A, McCrorey M, Salman T, Johnson D, Luo Z, Fu X NeuroImmune Pharm Ther. 2025; 3(3-4):183-193.
PMID: 39741560 PMC: 11683879. DOI: 10.1515/nipt-2024-0012.
Cannabinoids and triple-negative breast cancer treatment.
Dobovisek L, Borstnar S, Debeljak N, Brezar S Front Immunol. 2024; 15:1386548.
PMID: 39176080 PMC: 11338791. DOI: 10.3389/fimmu.2024.1386548.
The Impact of the CB Cannabinoid Receptor in Inflammatory Diseases: An Update.
Rakotoarivelo V, Mayer T, Simard M, Flamand N, Di Marzo V Molecules. 2024; 29(14).
PMID: 39064959 PMC: 11279428. DOI: 10.3390/molecules29143381.
The Effects of Nicotine and Cannabinoids on Cytokines.
Miller G, Pareek O, Penman S, Thanos P Curr Pharm Des. 2024; 30(31):2468-2484.
PMID: 38859790 DOI: 10.2174/0113816128293077240529111824.
Jafari N, Gheitasi R, Khorasani H, Golpour M, Mehri M, Nayeri K Heliyon. 2023; 9(9):e19238.
PMID: 37674821 PMC: 10477462. DOI: 10.1016/j.heliyon.2023.e19238.